Birchview Capital LP Sells 391,847 Shares of Karyopharm Therapeutics Inc. $KPTI

Key Points

• Birchview Capital LP significantly reduced its stake in Karyopharm Therapeutics by 93.3%, owning approximately 27,985 shares after selling 391,847 shares in the first quarter.
• Several institutional investors, including Two Sigma Advisers LP and Northern Trust Corp, have altered their positions in Karyopharm, contributing to 66.44% of the company's stock being owned by hedge funds and institutional investors.
• Analysts have mixed views on Karyopharm's stock, with target prices ranging from $25.00 to $34.00, while the company missed earnings expectations, reporting an EPS of ($4.32).

Birchview Capital LP reduced its holdings in shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) by 93.3% in the first quarter, according to its most recent filing with the SEC. The fund owned 27,985 shares of the company's stock after selling 391,847 shares during the period. Birchview Capital LP owned about 0.33% of Karyopharm Therapeutics worth $105,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Jane Street Group LLC raised its stake in Karyopharm Therapeutics by 265.5% in the fourth quarter. Jane Street Group LLC now owns 748,306 shares of the company's stock worth $506,000 after buying an additional 543,556 shares in the last quarter. Northern Trust Corp raised its position in shares of Karyopharm Therapeutics by 23.5% during the 4th quarter. Northern Trust Corp now owns 283,729 shares of the company's stock worth $192,000 after purchasing an additional 54,061 shares during the last quarter. Shay Capital LLC acquired a new stake in Karyopharm Therapeutics in the 4th quarter valued at about $116,000. T. Rowe Price Investment Management Inc. acquired a new stake in Karyopharm Therapeutics in the 1st quarter valued at about $523,000. Finally, Two Sigma Investments LP grew its stake in shares of Karyopharm Therapeutics by 60.3% in the 4th quarter. Two Sigma Investments LP now owns 137,786 shares of the company's stock valued at $93,000 after buying an additional 51,856 shares during the period. Institutional investors own 66.44% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Wall Street Zen cut shares of Karyopharm Therapeutics from a "hold" rating to a "sell" rating in a research report on Wednesday, May 14th. HC Wainwright downgraded shares of Karyopharm Therapeutics from a "buy" rating to a "neutral" rating in a report on Wednesday, July 16th. Royal Bank Of Canada decreased their price objective on shares of Karyopharm Therapeutics from $34.00 to $33.00 and set an "outperform" rating on the stock in a report on Tuesday, May 13th. Barclays boosted their price objective on shares of Karyopharm Therapeutics from $5.00 to $10.00 and gave the company an "overweight" rating in a research report on Tuesday, May 13th. Finally, Robert W. Baird decreased their price objective on shares of Karyopharm Therapeutics from $42.00 to $25.00 and set an "outperform" rating for the company in a research note on Tuesday, August 12th. Four research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $34.00.

Karyopharm Therapeutics Trading Down 2.1%

Shares of KPTI traded down $0.14 during midday trading on Friday, hitting $6.60. The stock had a trading volume of 49,872 shares, compared to its average volume of 206,918. The business has a 50-day simple moving average of $5.05 and a two-hundred day simple moving average of $5.31. The firm has a market cap of $57.22 million, a P/E ratio of -0.45 and a beta of 0.35. Karyopharm Therapeutics Inc. has a fifty-two week low of $3.51 and a fifty-two week high of $16.95.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The company reported ($4.32) earnings per share for the quarter, missing analysts' consensus estimates of ($3.80) by ($0.52). The firm had revenue of $37.93 million for the quarter, compared to analyst estimates of $37.92 million. Karyopharm Therapeutics has set its FY 2025 guidance at EPS. On average, analysts expect that Karyopharm Therapeutics Inc. will post -0.71 earnings per share for the current fiscal year.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).